Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This therapeutic regimen consists of the sequential administration of heparin and aspirin, evaluated by Guangdong Provincial People's Hospital for postoperative management in infants and neonates undergoing surgical repair for total anomalous pulmonary venous connection (TAPVC). The protocol involves a continuous infusion of heparin starting six hours postoperatively to maintain an activated coagulation time (ACT) of 160-180 seconds, followed by oral aspirin (5 mg/kg every eight hours) for three months after the removal of deep vein catheters. The primary goal of this anticoagulation strategy is to reduce the incidence of pulmonary venous obstruction (PVO), a major and often fatal complication following TAPVC repair.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on heparin + aspirin.